HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.

Abstract
The polyphenol epigallocatechin-3-gallate (EGCG), the principal mediator of the green tea, has been known to possess antitumor effect. The endothelin A receptor (ET(A)R)/endothelin-1 (ET-1) axis is overexpressed in ovarian carcinoma representing a novel therapeutic target. In this study, we examined the green tea and EGCG effects on two ovarian carcinoma cell lines, HEY and OVCA 433. EGCG inhibited ovarian cancer cell growth and induced apoptosis that was associated with a decrease in Bcl-X(L) expression and activation of caspase-3. Treatment with green tea or EGCG inhibited ET(A)R and ET-1 expression and reduced the basal and ET-1-induced cell proliferation and invasion. The EGCG-induced inhibitory effects were associated with a decrease of ET(A)R-dependent activation of the p42/p44 and p38 mitogen-activated protein kinases and phosphatidylinositol 3-kinase pathway. Remarkably, EGCG treatment resulted in a lowering of basal and ET-1-induced angiogenesis and invasiveness mediators, such as vascular endothelial growth factor and tumor proteinase activation. Finally, in HEY ovarian carcinoma xenografts, tumor growth was significantly inhibited by oral administration of green tea. This effect was associated with a reduction in ET-1, ET(A)R, and vascular endothelial growth factor expression, microvessel density, and proliferation index. These results provide a novel insight into the mechanism by which EGCG, affecting multiple ET(A)R-dependent pathways, may inhibit ovarian carcinoma growth, suggesting that EGCG may be useful in preventing and treating ovarian carcinoma in which ET(A)R activation by ET-1 plays a critical role in tumor growth and progression.
AuthorsFrancesca Spinella, Laura Rosanò, Valeriana Di Castro, Samantha Decandia, Adriana Albini, Maria Rita Nicotra, Pier Giorgio Natali, Anna Bagnato
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 5 Issue 6 Pg. 1483-92 (Jun 2006) ISSN: 1535-7163 [Print] United States
PMID16818507 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticarcinogenic Agents
  • Endothelin-1
  • Receptor, Endothelin A
  • Tea
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • bcl-X Protein
  • Catechin
  • epigallocatechin gallate
  • Phosphatidylinositol 3-Kinases
  • Mitogen-Activated Protein Kinases
  • Urokinase-Type Plasminogen Activator
  • CASP3 protein, human
  • Casp3 protein, mouse
  • Caspase 3
  • Caspases
Topics
  • Animals
  • Anticarcinogenic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Caspase 3
  • Caspases (metabolism)
  • Catechin (analogs & derivatives, pharmacology)
  • Cell Proliferation (drug effects)
  • Endothelin-1 (antagonists & inhibitors, pharmacology)
  • Enzyme Activation (drug effects)
  • Female
  • Humans
  • Mice
  • Mice, Nude
  • Mitogen-Activated Protein Kinases (metabolism)
  • Neoplasm Invasiveness
  • Ovarian Neoplasms (drug therapy, metabolism)
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Receptor, Endothelin A (metabolism)
  • Signal Transduction (drug effects)
  • Tea
  • Transplantation, Heterologous
  • Urokinase-Type Plasminogen Activator (antagonists & inhibitors)
  • Vascular Endothelial Growth Factor A (metabolism)
  • bcl-X Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: